| 产品描述: | Bleximenib (Menin-MLL inhibitor 24) oxalate 是一种 menin-mixed-lineage leukemia 1 (menin-MLL) 抑制剂,可用于癌症研究。;Menin-MLL inhibitor 24 (compound A) oxalate is a menin-mixed-lineage leukemia 1 (menin-MLL) inhibitor, and can be used for the research of cancer. |
| 体内研究: |
Bleximenib (0-100 mg/kg; 口服; 4-6 周) oxalate 在白血病小鼠模型中具有抗肿瘤的活性。 |
| 参考文献: |
1. Kwon MC, et al. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood. 2024 Sep 12;144(11):1206-1220. 2. Hogeling SM, et al. Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia. Haematologica. 2024 Dec 19. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.45 ml |
7.248 ml |
14.497 ml |
| 5 mM |
0.29 ml |
1.45 ml |
2.899 ml |
| 10 mM |
0.145 ml |
0.725 ml |
1.45 ml |
| 50 mM |
0.029 ml |
0.145 ml |
0.29 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |